AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Amphastar Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$26.14+0.27 (+1.04%)

Close on Oct 19, 2026

Market cap: $1.16B
P/E (TTM): 15.4
Dividend yield: –

Amphastar Pharmaceuticals, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	720	732	644	499	438	350	322	295	240	255	252	210	230	204
Cost of Revenue	364	358	293	250	238	207	190	188	150	151	174	159	143	114
Gross Profit	356	374	351	249	200	143	132	107	91	104	77	51	87	90
Research & Development	86	74	74	75	61	67	69	58	44	42	37	29	33	31
Selling, General & Admin	130	95	80	67	69	65	63	58	51	47	47	40	36	32
Selling & Marketing	44	38	29	22	17	15	13	8.16	6.46	5.47	5.47	5.56	5.35	4.43
General & Administrative	86	57	52	45	51	50	50	50	44	42	42	35	31	27
Operating Expenses	216	168	154	141	130	132	132	116	92	89	84	69	69	65
Operating Income	140	205	197	107	70	11	-0.04	-8.62	-1.27	15	-6.90	-18	17	25
Interest Expense	25	30	27	1.85	0.89	0.37	0.12	0.24	0.83	1.02	0.99	0.61	0.96	0.78
Interest & Investment Income	8.68	11	5.46	1.32	0.60	0.64	1.00	0.46	0.43	0.27	0.32	0.24	0.19	0.24
Income from Equity Investments	–	-0.57	-1.98	-1.18	-0.21	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-17	-16	-26	8.54	14	-6.32	60	-1.30	2.52	-0.75	-3.47	-0.17	-0.26	0.48
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	0.21	0.44	0.13	2.09
Gain (Loss) on Sale of Assets	-0.04	-0.01	-0.48	-0.14	-0.35	-0.24	-1.04	-1.43	2.34	-1.24	-0.31	-0.49	-0.09	-0.61
Pretax Income	124	190	171	116	84	4.64	60	-9.93	1.25	15	-10	-18	17	26
Income Tax Expense	26	30	32	23	21	3.54	14	-3.27	-2.40	4.81	-7.58	-7.45	5.37	7.78
Net Income incl. Noncontrolling Interests	98	160	138	91	63	1.10	47	-6.66	3.65	9.82	–	–	–	–
Minority Interest in Earnings	–	–	–	–	1.19	-0.31	-2.43	-0.92	–	–	–	–	–	–
Net Income	98	160	138	91	62	1.40	49	-5.74	3.65	9.82	-2.79	-11	12	18
EPS (Basic)(per share)	2.10	3.29	2.85	1.88	1.30	0.03	1.04	-0.12	0.08	0.22	-0.06	-0.25	0.31	0.47
EPS (Diluted)(per share)	2.03	3.06	2.60	1.74	1.25	0.03	0.98	-0.12	0.08	0.21	-0.06	-0.25	0.31	0.46
Shares Outstanding (Basic, Weighted)(shares)	47	48	48	49	48	47	47	46	46	45	45	42	39	39
Shares Outstanding (Diluted, Weighted)(shares)	48	52	53	52	50	49	50	46	48	48	45	42	39	39
EBITDA	–	–	223	120	80	20	7.02	-2.57	5.15	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 47.7%
Operating margin: 15.7%
Net margin: 10.8%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.40
Debt to equity: –
Debt to assets: 35.1%
Cash to current liabilities: 85.0%

Valuation

P/E ratio: 15.4
Price to sales: 1.58
Price to book: –
Dividend yield: –